Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/114099
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWallington-Beddoe, C.en
dc.contributor.authorSobieraj-Teague, M.en
dc.contributor.authorKuss, B.en
dc.contributor.authorPitson, S.en
dc.date.issued2018en
dc.identifier.citationBritish Journal of Haematology, 2018; 182(1):11-28en
dc.identifier.issn0007-1048en
dc.identifier.issn1365-2141en
dc.identifier.urihttp://hdl.handle.net/2440/114099-
dc.description.abstractThe number of novel therapies for the treatment of myeloma is rapidly increasing, as are the clinical trials evaluating them in combination with other novel and established therapies. Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies are the most well known and studied classes of novel agents targeting myeloma, with histone deacetylase inhibitors, nuclear export inhibitors and several other approaches also being actively investigated. However, in parallel with the development and clinical use of these novel myeloma therapies is the emergence of novel mechanisms of resistance, many of which remain elusive, particularly for more recently developed agents. Whilst resistance mechanisms have been best studied for proteasome inhibitors, particularly bortezomib, class effects do not universally apply to all class members, and within-class differences in efficacy, toxicity and resistance mechanisms have been observed. Although immunomodulatory agents share the common cellular target cereblon and thus resistance patterns relate to cereblon expression, the unique cell surface antigens to which monoclonal antibodies are directed means these agents frequently exhibit unique within-class differences in clinical efficacy and resistance patterns. This review describes the major classes of novel therapies for myeloma, highlights the major clinical trials within each class and discusses known resistance mechanisms.en
dc.description.statementofresponsibilityCraig T. Wallington‐Beddoe, Magdalena Sobieraj‐Teague, Bryone J. Kuss Stuart M. Pitsonen
dc.language.isoenen
dc.publisherWileyen
dc.rights© 2018 John Wiley & Sons Ltd.en
dc.subjectimmunomodulatory agent; monoclonal antibody; myeloma; novel therapy; proteasome inhibitor; resistance mechanismsen
dc.titleResistance to proteasome inhibitors and other targeted therapies in myelomaen
dc.typeJournal articleen
dc.identifier.rmid0030086364en
dc.identifier.doi10.1111/bjh.15210en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1071945en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1042589en
dc.identifier.pubid406505-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS10en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidWallington-Beddoe, C. [0000-0002-7457-5937]en
dc.identifier.orcidPitson, S. [0000-0002-9527-2740]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.